Neusoft Medical’s Cardiology CAD Software Gets SFDA Nod
This article was originally published in PharmAsia News
Neusoft Medical System has received China's State FDA approval for its Cardiology Computer-Aided Diagnosis (CAD) 2.0 system. This is the second SFDA certification for the company's CAD software, the first being MammoCAD. Clinical testing of CardioCAD2.0 shows that its effectiveness and safety standards are equal to world-class products, providing doctors an analysis platform of heart vessel CT images. CardioCAD's successful development by a Chinese firm represents a significant milestone for the specialized field; it not only breaks the monopoly MNCs hold in domestic and international markets, but also brings new choices to the health care industry. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.